Andre Franke1, Corinna Bang2, Malte Christoph Rühlemann1, Miriam Emmy Leni Solovjeva1, Roman Zenouzi3, Timur Liwinski3, Martin Kummen4,5, Wolfgang Lieb6, Johannes Roksund Hov4,5, Christoph Schramm3,7. 1. Institute of Clinical Molecular Biology, Christian-Albrechts-Universität zu Kiel, Kiel, Germany. 2. Institute of Clinical Molecular Biology, Christian-Albrechts-Universität zu Kiel, Kiel, Germany c.bang@ikmb.uni-kiel.de. 3. Department of Internal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. 4. Norwegian PSC Research Center, Oslo University Hospital, Rikshospitalet, Oslo, Norway. 5. Institute of Clinical Medicine, University of Oslo, Oslo, Norway. 6. Institute of Epidemiology and Biobank POPGEN, Christian-Albrechts-University of Kiel, Kiel, Germany. 7. Martin Zeitz Centre for Rare Diseases, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
We read with interest the recent Gut article by Lemoinne et al describing a dysbiosis of the fungal gut community in faeces of patients suffering from primary sclerosing cholangitis (PSC).1 Though several reports, including our own previous data, support a functional and potentially pathogenic link between the intestinal bacteriota and liver inflammation in PSC,2 3 the aetiology of the disease remains largely unknown.We here report on the fungal mycobiome results of our cohort from Northern Germany approved by the local ethics committees (A148/14 and MC-111/15) comprising stool samples of 66 healthy control (HC) subjects, 65 patients with well-characterised PSC (including a subgroup with concomitant colitis (PSC-IBD), n=32) and 38 subjects with UC.3 PCR and sequencing of the fungus-specific internal transcribed spacer 2 genomic region was performed as previously described4 using the primer pair 5.8S-Fun and ITS4-Fun on an Illumina MiSeq machine. Sequencing data were subjected to quality control by using the open source package DADA2 (V.1.10)5 in R (V.3.5.1; https://github.com/mruehlemann/ikmb_amplicon_processing). Amplicon sequence variants were taxonomically annotated using the UNITE ITS database (V.7.2).6In disagreement with the findings in the French cohort,1 overall fungal alpha diversity in the German cohort was neither altered in PSC nor in UC versus HC as calculated by Shannon species equivalent (figure 1A). None of the disease groups significantly deviated in community composition from healthy individuals (all padonis >0.05; figure 1B). Fungal composition on phylum level was found to be mainly dominated by Ascomycota (figure 1C), particularly by the genera Saccharomyces, Candida and Dipodascus (figure 1D) in relatively higher abundance of reads when compared with the findings of Lemoinne et al.1 Though our results generally validate the previously described overall fungal composition in stool, we were not able to detect the genus Exophiala, which was found in five PSC patients from France exclusively. Whether this is due to methodological differences (choice of primer sets, data analysis tools and sampling depth) or presence of this fungus in only a subset of PSC patients not sampled in the German cohort needs to be determined.
Figure 1
Mycobiome of individuals with primary sclerosing cholangitis (PSC) and UC as well as healthy controls (HC) (all of northern German origin). Rarefaction curves for Shannon diversity of sequence variants reached plateau between 50 and 100 sequences per samples, thus samples were normalised to 100 random reads per sample. (A) Alpha diversity as presented by Shannon species equivalents (all p>0.05). (B) Beta diversity ordination of the Bray-Curtis dissimilarity based on genus-level fungal abundances (all padonis >0.05). (C) Phylum-level and (D) genus-level mean abundances of all taxa with >1% mean abundance and present in at least 10 samples. (E) Group-wise box-and-whisker plots for significant genus level annotations tested for differential abundances with individual values represented as data points. (F) Differences in group-mean abundances of patients with PSC and UC, as compared with HC. *q<0.05, **q<0.01.
Mycobiome of individuals with primary sclerosing cholangitis (PSC) and UC as well as healthy controls (HC) (all of northern German origin). Rarefaction curves for Shannon diversity of sequence variants reached plateau between 50 and 100 sequences per samples, thus samples were normalised to 100 random reads per sample. (A) Alpha diversity as presented by Shannon species equivalents (all p>0.05). (B) Beta diversity ordination of the Bray-Curtis dissimilarity based on genus-level fungal abundances (all padonis >0.05). (C) Phylum-level and (D) genus-level mean abundances of all taxa with >1% mean abundance and present in at least 10 samples. (E) Group-wise box-and-whisker plots for significant genus level annotations tested for differential abundances with individual values represented as data points. (F) Differences in group-mean abundances of patients with PSC and UC, as compared with HC. *q<0.05, **q<0.01.Disease-associated differential abundance of fungal taxa was investigated by applying Student’s t-test to the arcsin-squareroot-transformed relative abundances of all genera with mean abundance >1% and present in at least 10 individuals. This analysis revealed increased levels of the genera Candida and Humicola (species level annotation suggests H. grisea) in PSC patients with and without concomitant colitis compared with HC (all qBH <0.05; figure 1E and F) and UC (all qBH <0.1; figure 1E) individuals. H. grisea, recently reclassified as Trichocladium griseum,7 belongs to the fungal class Sordariomycetes, thus our results reproduce the significant increase of this class in PSC patients, as previously described by Lemoinne and colleagues, but at increased taxonomic resolution. Previous research on T. griseum showed that it is most frequently isolated from soil and plants but also occasionally found in patients suffering from peritonitis.8 In addition, the validated increase of Candida species in PSC patients argues for an immunogenic role of these fungi, particularly with respect to earlier findings that demonstrated their high potential to induce Th17 response in T cells.9 Increased Th17 numbers have previously been reported in PSC patients and recently been shown to be involved in PSC pathogenesis.10In summary, both the significant increase of the fungal class Sordariomycetes, likely T. griseum, as well as of Candida species in stool samples of PSC patients, now found in two independent and geographically distinct PSC patient panels that were analysed with divergent methodological approaches, strongly demands for additional analyses on these fungi and their role in PSC.
Authors: X W Wang; F Y Yang; M Meijer; B Kraak; B D Sun; Y L Jiang; Y M Wu; F Y Bai; K A Seifert; P W Crous; R A Samson; J Houbraken Journal: Stud Mycol Date: 2018-08-07 Impact factor: 16.097
Authors: Sara Lemoinne; Astrid Kemgang; Karima Ben Belkacem; Marjolène Straube; Sarah Jegou; Christophe Corpechot; Olivier Chazouillères; Chantal Housset; Harry Sokol Journal: Gut Date: 2019-04-19 Impact factor: 23.059
Authors: Martin Kummen; Kristian Holm; Jarl Andreas Anmarkrud; Ståle Nygård; Mette Vesterhus; Marte L Høivik; Marius Trøseid; Hanns-Ulrich Marschall; Erik Schrumpf; Bjørn Moum; Helge Røsjø; Pål Aukrust; Tom H Karlsen; Johannes R Hov Journal: Gut Date: 2016-02-17 Impact factor: 23.059
Authors: Janosch Katt; Dorothee Schwinge; Tanja Schoknecht; Alexander Quaas; Ingo Sobottka; Eike Burandt; Christoph Becker; Markus F Neurath; Ansgar W Lohse; Johannes Herkel; Christoph Schramm Journal: Hepatology Date: 2013-07-30 Impact factor: 17.425
Authors: Benjamin J Callahan; Paul J McMurdie; Michael J Rosen; Andrew W Han; Amy Jo A Johnson; Susan P Holmes Journal: Nat Methods Date: 2016-05-23 Impact factor: 28.547
Authors: D Lee Taylor; William A Walters; Niall J Lennon; James Bochicchio; Andrew Krohn; J Gregory Caporaso; Taina Pennanen Journal: Appl Environ Microbiol Date: 2016-11-21 Impact factor: 4.792
Authors: Rolf Henrik Nilsson; Karl-Henrik Larsson; Andy F S Taylor; Johan Bengtsson-Palme; Thomas S Jeppesen; Dmitry Schigel; Peter Kennedy; Kathryn Picard; Frank Oliver Glöckner; Leho Tedersoo; Irja Saar; Urmas Kõljalg; Kessy Abarenkov Journal: Nucleic Acids Res Date: 2019-01-08 Impact factor: 16.971
Authors: Malte Rühlemann; Timur Liwinski; Femke-Anouska Heinsen; Corinna Bang; Roman Zenouzi; Martin Kummen; Louise Thingholm; Marie Tempel; Wolfgang Lieb; Tom Karlsen; Ansgar Lohse; Johannes Hov; Gerald Denk; Frank Lammert; Marcin Krawczyk; Christoph Schramm; Andre Franke Journal: Aliment Pharmacol Ther Date: 2019-06-28 Impact factor: 8.171